Patents Assigned to EUSA PHARMA (UK) LIMITED
  • METHOD FOR TREATING A GD2-POSITIVE CANCER
    Publication number: 20230295339
    Abstract: A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m2, and/or in a dose of up to 100 mg/m2 per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m2/day.
    Type: Application
    Filed: July 6, 2021
    Publication date: September 21, 2023
    Applicant: EUSA PHARMA (UK) LIMITED
    Inventors: Holger Nikolaus LODE, Ruth LADENSTEIN